IRVINE, Calif., March 1, 2017 /PRNewswire/ -- Syneron
Medical Ltd. (NASDAQ: ELOS), a global market leader in the
aesthetic medical device marketplace, will unveil expansions of
technologies during the 2017 American Academy of Dermatology (AAD)
meeting in Orlando, Fla. The
advancements clearly demonstrate Syneron Candela's commitment to
providing innovative treatment solutions for various skin and body
conditions in the aesthetic and wellness marketplace.
- GentleTouch, a state-of-the-art, solid-state laser system adds
CE mark approval to the FDA clearance and joins the Company's
portfolio as the first and only device to combine Alexandrite and
radiofrequency energies to remove hair safely. Equipped with three
operating modes, GentleTouch ensures all hair removal treatments
are customizable to the particular needs of each patient. The
system additionally includes EverCool, a unique, patent-pending,
contact-cooling method and is cleared for hair removal on all skin
types (Fitzpatrick I-VI).
- PicoWay, a leading solution for tattoo removal and treatment of
benign, pigmented lesions, received FDA clearance for the treatment
of acne scars in Fitzpatrick Skin Types II-V for the Resolve
holographic 1064 nm wavelength handpiece. By targeting acne scars
with high peak power and the shortest pulses available at that
wavelength, PicoWay Resolve quickly and effectively treats the
appearance of acne scars with minimal patient downtime and side
effects.
- UltraShape Power, the first and only non-invasive fat reduction
system that uses pulsed, focused ultrasound, will be featured as
the newest addition to the body contouring portfolio. When compared
to the prior version of UltraShape, the UltraShape Power features a
20% increase in ultrasound power delivered to tissue and an average
treatment time of 30 minutes for a typical abdomen. The FDA
clinical study demonstrated more than a 30% reduction in fat
thickness following a three session treatment protocol.
- Profound, recently FDA cleared to improve the appearance of
cellulite, is a minimally invasive, fractional radiofrequency
microneedling device. Specifically, the 25º Dermal handpiece and
cartridge are used for percutaneous treatment of facial wrinkles,
and the 75º SubQ handpiece and cartridge are used to improve the
appearance of cellulite in patients with Fitzpatrick Skin Types
I-III as supported by long-term clinical data.
"Clinical data to support the efficacy of new products, new
indications and safety of our current and new portfolios will
continue to be a focus of Syneron Candela," says Philippe Schaison,
CEO of Syneron Candela, North
America. "Recent advancements of UltraShape Power,
GentleTouch, PicoWay and Profound illustrate Syneron Candela's
dedication to finding innovative solutions for a variety of
patients' aesthetic needs."
Visit the Syneron Candela booth #2953 at the AAD annual meeting
to learn more.
About Syneron Candela:
Syneron Candela is a leading global aesthetic device company with a
comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to provide
advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, tattoo removal, women's intimate health, improving the
skin's appearance through the treatment of superficial benign
vascular and pigmented lesions, and the treatment of acne, leg
veins and cellulite. The Company has a wide portfolio of trusted,
leading products including UltraShape Power, VelaShape, CO2RE,
CO2RE Intima, GentleLase, VBeam Perfecta, PicoWay, Profound and
elōs Plus.
Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Candela are located in Israel.
Syneron Candela also has R&D and manufacturing operations in
the U.S. The company markets, services and supports its
products in 86 countries. It has offices in North
America, France, Germany, Italy, Portugal, Spain,
UK, Australia, China, Japan, and Hong
Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including potential clinical successes, market acceptance
of new products, and projected revenues, margins, earnings and
market shares. The statements made by the Company are based upon
management's current expectations and are subject to certain risks
and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include the risk factors and other
cautionary statements described in the Company's filings with the
SEC, including those described in the Company's most recent Annual
Report on Form 20-F, and in the filings that Syneron Medical makes
with the SEC, and other factors beyond the Company's control. If
one or more of these factors materialize, or if any underlying
assumptions prove incorrect, Syneron Medical Ltd.'s actual results,
performance or achievements may vary materially from those
expressed or implied by these forward-looking statements.
These forward-looking statements should not be relied upon as
representing Syneron Medical Ltd.'s views as of any date after the
date of this document. The Company does not intend to update these
statements and undertakes no duty to any person to provide any such
update under any circumstance.
For additional information, please
visit http://www.syneron-candela.com.
Media contact:
Heidi
Donato, Cohn & Wolfe
E: Heidi.Donato@cohnwolfe.com
M: 516-359-1146
P: 516-221-0614
Investor Relations contact:
Zack Kubow, The Ruth Group
E: zkubow@theruthgroup.com
P: 646-536-7020
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/syneron-candela-announces-new-technology-and-indications-at-the-2017-american-academy-of-dermatology-aad-annual-meeting-300416266.html
SOURCE Syneron Candela